| Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials CEM Griffiths, K Reich, M Lebwohl, P van de Kerkhof, C Paul, A Menter, ... The Lancet 386 (9993), 541-551, 2015 | 811 | 2015 |
| Phase 3 studies comparing brodalumab with ustekinumab in psoriasis M Lebwohl, B Strober, A Menter, K Gordon, J Weglowska, L Puig, K Papp, ... New England Journal of Medicine 373 (14), 1318-1328, 2015 | 757 | 2015 |
| Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey MG Lebwohl, H Bachelez, J Barker, G Girolomoni, A Kavanaugh, ... Journal of the American Academy of Dermatology 70 (5), 871-881. e30, 2014 | 522 | 2014 |
| Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children U Wahn, JD Bos, M Goodfield, R Caputo, K Papp, A Manjra, A Dobozy, ... Pediatrics 110 (1), e2-e2, 2002 | 506 | 2002 |
| Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study CF Paul, VC Ho, C McGeown, E Christophers, B Schmidtmann, ... Journal of investigative dermatology 120 (2), 211-216, 2003 | 453 | 2003 |
| Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled … C Paul, J Cather, M Gooderham, Y Poulin, U Mrowietz, C Ferrandiz, ... British Journal of Dermatology 173 (6), 1387-1399, 2015 | 436 | 2015 |
| A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis KA Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, ... British Journal of Dermatology 175 (2), 273-286, 2016 | 428 | 2016 |
| First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open … P Joly, M Maho-Vaillant, C Prost-Squarcioni, V Hebert, E Houivet, S Calbo, ... The Lancet 389 (10083), 2031-2040, 2017 | 426 | 2017 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ... Anaesthesia 76 (6), 748-758, 2021 | 407 | 2021 |
| Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug A Kapp, K Papp, A Bingham, R Fölster-Holst, JP Ortonne, PC Potter, ... Journal of Allergy and Clinical Immunology 110 (2), 277-284, 2002 | 397 | 2002 |
| Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review C Horreau, C Pouplard, E Brenaut, T Barnetche, L Misery, B Cribier, ... Journal of the European Academy of Dermatology and Venereology 27, 12-29, 2013 | 379 | 2013 |
| Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis C Paul, P Wolkenstein, H Adle, J Wechsler, HJ Garchon, J Revuz, ... British Journal of Dermatology 134 (4), 710-714, 1996 | 371 | 1996 |
| Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study P Rich, B Sigurgeirsson, D Thaci, JP Ortonne, C Paul, RE Schopf, ... British Journal of Dermatology 168 (2), 402-411, 2013 | 369 | 2013 |
| Carcinogenic risks of psoralen UV‐A therapy and narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review E Archier, S Devaux, E Castela, A Gallini, F Aubin, M Le Maître, ... Journal of the European Academy of Dermatology and Venereology 26, 22-31, 2012 | 346 | 2012 |
| Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis FM Arellano, CE Wentworth, A Arana, C Fernández, CF Paul Journal of Investigative dermatology 127 (4), 808-816, 2007 | 334 | 2007 |
| Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE) C Paul, JP Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, ... Journal of the European Academy of Dermatology and Venereology 29 (6), 1082-1090, 2015 | 317 | 2015 |
| What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature E Puzenat, V Bronsard, S Prey, PA Gourraud, S Aractingi, M Bagot, ... Journal of the European Academy of Dermatology and Venereology 24, 10-16, 2010 | 304 | 2010 |
| The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double‐blind controlled study C Queille‐Roussel, C Paul, L Duteil, MC Lefebvre, G Rapatz, M Zagula, ... British Journal of Dermatology 144 (3), 507-513, 2001 | 298 | 2001 |
| Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis AP Villani, M Rouzaud, M Sevrain, T Barnetche, C Paul, MA Richard, ... Journal of the American Academy of Dermatology 73 (2), 242-248, 2015 | 294 | 2015 |
| Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study B Sigurgeirsson, JH Ólafsson, J þ Steinsson, C Paul, S Billstein, ... Archives of Dermatology 138 (3), 353-357, 2002 | 268 | 2002 |
Denis JULLIENUniversité Claude Bernard Lyon-I, Hospices Civils de LyonVerified email at chu-lyon.fr
